V920

BIOLOGICAL2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Ebola VirusEbola Viruses

Phase 1

Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001)

CompletedNCT02269423

Merck Sharp & Dohme LLCEbola Virus

Start: 2014-10-13End: 2015-08-25Updated: 2019-10-23

Safety and Immunogenicity of Prime-Boost Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-002)

CompletedNCT02280408

Merck Sharp & Dohme LLCEbola Viruses

Start: 2014-10-07End: 2015-12-10Updated: 2019-07-12

Related Papers

Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic.

2017-06-2135 citations

A Recombinant Vesicular Stomatitis Virus Ebola Vaccine

New England Journal of Medicine2015-04-02380 citations